Skip to Content

'
Sheeba Koshy Thomas, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2009 UT School of Medicine, Houston, TX, MS, Clinical Research
1999 Boston University, Boston, MA, BA, Medical Sciences
1999 Boston University, Boston, MA, MD, Medicine

Postgraduate Training

7/2002-6/2005 Clinical Fellowship, Medical Oncology and Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert A. Wolff, M.D.
6/1999-6/2002 Clinical Residency, Internal Medicine, Temple University Hospital, Philadelphia, PA, Richard S. Eisenstadt, M.D.

Board Certifications

2016 American Board of Internal Medicine, Hematology
2015 American Board of Internal Medicine, Medical Oncology
2012 American Board of Internal Medicine, Internal Medicine

Experience/Service

Academic Appointments

Clinical Specialist, Department of Internal Medicine, Division of Internal Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 8/2002-6/2005

Institutional Committee Activities

Member, Committee on Guidelines for Chemotherapy-induced Nausea and Vomiting, 9/2007-8/2013
Member, Clinical Ethics Committee, 9/2007-8/2009
Member, Clinical Research Committee, 7/2006-present

Honors and Awards

2004 Young Investigator Award, American Society of Clinical Oncology
2003 Aventis Award, Department of Thoracic Head & Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center
2003 Jesse H. Jones Clinical Research Fellowship Award, University of Texas M.D. Anderson Cancer Center
1999 Bachelor of Arts, magna cum laude, Boston University
1996 Summer Fellowship Grant, American Society of Hematology
1995 Dean's List, Boston University
1994 Golden Key National Honor Society, National Honor Society
1992-1995 University Scholar, Boston University

Professional Memberships

American Society of Clinical Oncology
Member, 2003-present
American Society of Hematology
Member, 2006-present
Harris County Medical Society, Houston, TX
Member, 2007-present
Massachusetts Medical Society, MA
Member, 1995-present
Southwest Oncology Group
Member, 2007-present
Texas Medical Association, TX
Member, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with Gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-331, 2006. PMID: 16640804.
2. Popat U, Saliba R, Thandi R, Hosing C, Sphall E, McMannis J, Korbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):713-723, 2009. PMID: 19450756.
3. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation 45. e-Pub 7/2009.
4. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 10/2010. e-Pub 8/2010. PMCID: PMC2966770.
5. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 3/2011. e-Pub 1/17/2011. PMCID: PMC3402914.
6. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 3/17/2011. e-Pub 11/8/2010. PMID: 21057542.
7. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 10/1/2011. e-Pub 3/22/2011. PMID: 21437886.
8. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 1/2012. e-Pub 8/24/2011. PMID: 21780997.
9. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 3/2012. e-Pub 1/9/2012. PMID: 22231283.
10. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. J Pain 13(6):564-70, 6/2012. e-Pub 4/28/2012. PMCID: PMC3367066.
11. Thomas SK, Kwak LW. Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial. Semin Oncol 39(3):253-62, 6/2012. PMID: 22595048.
12. Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M.S. Anderson sympton inventory multiple myeloma module. J Hematol Oncol 6:13, 2013. e-Pub 2/5/2013. PMCID: PMC3598689.
13. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 6/2012. e-Pub 12/2011. PMID: 22207485.
14. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(16):3260-70, 10/18/2012. e-Pub 8/29/2012. PMCID: PMC3476538.
15. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161(3):357-66, 5/2013. e-Pub 2/25/2013. PMID: 23432640.
16. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. e-Pub 4/2013. PMID: 23545991.
17. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol 71(6):1531-40, 6/2013. e-Pub 3/31/2013. PMCID: PMC3669643.
18. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/13/2013. PMCID: PMC3874423.
19. Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, Zimmerman TM, van de Velde H, Bandekar R, Puchalski TA, Qi M, Uhlar C, Samoylova OS. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 73(1):35-42, 1/2014. e-Pub 10/23/2013. PMID: 24149943.
20. Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM. Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. J Clin Oncol. e-Pub 8/2014. PMID: 25154818.

Invited Articles

1. Thomas S, Alexanian R. Current treatment strategies for multiple myeloma. Clin Lymphoma Myeloma 7 Suppl 4:S139-44, 2007. PMID: 17562251.
2. Thomas SK, Richards TA, Weber DM. Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 20(4)(4):717-735, 2007. PMID: 18070715.
3. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-159, 2/2009. e-Pub 3/2009. PMCID: PMC2697512.
4. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer 15(6):485-93, 11/2009.

Abstracts

1. Koshy S, Herbst RS, Obasaju CK, Fossella FV, Papadimitrakopoulou VA, Blumenschein G, Peeples BO, Gladish G, Hong WK, Zinner RG. A phase II trial of pemetrexed (P) plus carboplatin (C) in patients with advanced non-small-cell lung cancer. JCO 22:7074, 2004.
2. Reiling RB, Wade JL, Govindan R, Wozniak AJ, Hensing TA, Koshy S, Thienelt CD, Natale RB, Belani CP. Clinical benefit with compassionate use Gefitinib (Iressa®) in a subset of non-small-cell lung cancer patients with the bronchoalvealor subtype treated during an expanded access program (EAP). JCO 22(14S):7087, 2004.
3. Tsao AS, Liu D, Koshy S, Herbst R, Lee J, Hong WK, Kies M. Smoking impacts response in NSCLC patients treated with Gefitinib. AACR-JCA Meeting, 2004.
4. Koshy S, Fossella F, Liu D, Schaerer R, Tsao A, Kies M, Pisters K, Lee J, Herbst R, Zinner R. Asian ethnicity as a predictor of response to Gefitinib in non-small cell lung cancer. 11th World Conference on Lung Cancer, 2005.
5. Thomas S, Burton A, Yao K, Villareal H, Fukshansky M, Are M, Suki D, Mendel E, Rhines L, Weber D, Alexanian R. Percutaneous vertebroplasty and/or kyphoplasty is an effective and safe treatment for painful vertebral compression fractures in multiple myeloma (MM). JCO 24(18S):7610, 2006.
6. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 108(11):123a (abstr 403), 2006.
7. Thomas S, Giralt S, Wang M, Delasalle KB, Gavino M, Rankin K, Alexanian R, Weber DM. Survival outcomes of patients receiving thalidomide-dexamethasone for previously untreated multiple myeloma. Blood 108(11):1019a (abstr 3569), 2006.
8. Richards T, Horowitz S, Temple S, Nguyen C, Thomas S, Wang M, Giralt S, Weber DM. Evaluation of multiple myeloma response by free light chain assay. Haematologica 92(6):205 (abstr PO-1015), 2007.
9. Thomas SK, Delasalle KB, Gavino M, Wang M, Alexanian R, Weber DM. 2-CDA-cyclophosphamide +/- Rituximab for symptomatic Waldenstrom's Macroglobulinemia. Haematologica 92(6):228, (abstr PO-1227), 2007.
10. Wang M, Delasalle K, Thomas S, Qazilbash M, Giralt S, Weber D, Alexanian R. Early transplant is useful for older patients with multiple myeloma. Haematologica 92(6):189 (abstr PO-819), 2007.
11. Delasalle K, Wang M, Thomas S, Weber D, Alexanian R. High response rate with BCD combination for relapsing multiple myeloma. Haematologica 92(6):158 (abstr PO-616), 2007.
12. Vadhan-Raj S, Weber D, Wang M, Giralt S, Alexanian R. Thomas S, Zhou X, Patel P, Bueso-Ramos C, Newman R, Aggarwal B. Curcumin downregulates NF-КB and related genes in patients with multiple myeloma: Results of a phase 1/2 study. Blood 110(11):357a, (abstr 1177), 2007.
13. Wright J, Weber D, Thomas S, Wang M, Alexanian R, Hawkins V, Vadhan-Raj S. Characteristics of patients experiencing thromboembolic events during treatment of multiple myeloma: Aspirin may not be adequate as thromboprophylaxis in patients with multiple risk factors. Blood 110(11):557a, (abstr 1882), 2007.
14. Giralt S, Thandi R, Qazilbash M, Mendoza F, Han E, Hosing C, Wang M, Thomas S, Alexanian R, Champlin R, Weber D. Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy with thalidomide/dexamethasone (TD) with or without bortezomib (VTD). Blood 110(11):890a, 2007.
15. Thomas SK, Hosing C, Delasalle KB, Gavino M, Popat UR, Qazilbash MH, Giralt S, Weber DM. Success rates of autologous stem cell collection in patients with Waldenstrom's Macroglobulinemia. Blood. Submitted.
16. Rakkhit R, Jooma N, Delasalle K, Gavino M, Dimopoulos M, Thomas S, McLaughlin P, Alexanian R, Weber D. Incidence of transformation to large cell lymphoma and of second malignancies in symptomatic patients with Waldenstrom's Macroglobulinemia (WM) treated with Cladribine (2-CdA) combination induction therapy. Blood 112(3065), 2008.
17. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Korbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, Marcos D, Weber DM, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Blood 15(6):718-23, 2009. PMID: 19450756.
18. Thomas S, Hosing C, Delasalle K, Gavino M, Popat U, Qazilbash M, Giralt S, Weber D, Alexanian R. Success rates of autologous stem cell collection in patients with Waldenstrom Macroglobulinemia. 5th International Workshop on Waldenstrom's Macroglobulinemia Stockholm. In Press.

Book Chapters

1. Thomas S, Richards T, Weber DM. Lenalidomide in relapsed or refractory multiple myeloma. Myeloma therapy: Pursuing the Plasma Cell. In: Myeloma Therapy, Contemporary Hematology series. Ed(s) S Lonial. The Humana Press, Inc. Totowa, NJ. In Press.
2. Thomas S, Richards T, Weber DM. Novel agents for previously untreated multiple myeloma. In: Multiple Myeloma. Ed(s) I. Ghobrial, M.D., K. Anderson, M.D. Informa Healthcare: New York. In Press.
3. Thomas S, Wang M, Weber D. Abnormal serum protein electrophoresis. In: Decision Making in Medicine, An Algorithmic Approach. Mosby, Inc: Philadelphia, 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Thomas S. Multiple Myeloma: Questions and Answers. M.D. Anderson Cancer Center: Houston, 2005.

Grant & Contract Support

Title: Phase I Study of Pomalidomide in relapsed or refractory Waldenström’s macroglobulinemia
Funding Source: Celgene
Role: Principal Investigator
Duration: 10/28/2010 - 8/31/2016
 
Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma, Project 2
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/22/2010 - 8/31/2015
 
Title: Mechanisms of Symptoms of Multiple Myeloma and Its Therapy, Prevention of Treatment Induced Neuropathy in Patients with Multiple Myeloma
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Charles Cleeland
Duration: 7/1/2008 - 6/30/2013
 
Title: Phase II Study of CNTO 328 (Anti-IL6 Antibody in subjects with Relapsed or Refractory Myeloma
Funding Source: Centocor
Role: Principal Investigator
Duration: 5/12/2008 - present
 
Title: Phase 2 Study of CNTO 328 (Anti-IL6 Antibody) in subjects with Relapsed or Refractory Myeloma
Funding Source: Centocor
Role: Principal Investigator
Duration: 2/14/2008 - present
 
Title: Database of Patients with Plasma Cell Dyscrasias.
Funding Source: M.D. Anderson Cancer Center-Execution and Control Budget Phase
Role: Principal Investigator
Duration: 12/1/2007 - 8/31/2009
 
Title: Database of Patients with Plasma Cell Dyscrasias
Funding Source: M.D. Anderson Cancer Center, Analysis & Planning Phase
Role: Principal Investigator
Duration: 9/6/2006 - 9/6/2007
 
Title: Phase I Study of an active immunotherapy for asymptomatic lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion
Funding Source: pending
Role: Principal Investigator
 
Title: A Phase I/II Study of hLL1-Dox (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients with Multiple Myeloma
Funding Source: Immunomedics
Role: Principal Investigator
 
Title: Phase II Study of Everolimus (Rad 001) in Previously Untreated Symptomatic Waldenström's Macroglobulinemia
Funding Source: Novartis
Role: Principal Investigator

Last updated: 7/28/2014